Ads
related to: autoantibody against somatostatin and depression treatment reviewsdoconsumer.com has been visited by 100K+ users in the past month
quizntales.com has been visited by 1M+ users in the past month
consumerhorse.com has been visited by 100K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent. [ 4 ] [ 5 ] In December 2014, the US FDA approved lanreotide for the treatment of people with unresectable, well or moderately differentiated, locally advanced or metastatic ...
Ibritumomab tiuxetan (pronounced / ɪ b r ɪ ˈ t uː m oʊ m æ b t aɪ ˈ ʌ k s ɛ t æ n / [2]), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma.
As somatostatin can cause inhibition of hormone production that uses it as a mediating hormone, it has an antiproliferative effect on cell tumors, especially in neuroendocrine tumors. [2] Somatostatin analogue therapy uses longer-acting agonists than the endogenous somatostatin to extend the antiproliferative effects. [24]
It is a non-selective somatostatin receptor antagonist, [37] inhibiting the effects of somatostatin on target cells in the gastrointestinal tract, pancreas, hypothalamus, and central nervous system. [2] Cyclosomatostatin is used as a research chemical to investigate the effects of somatostatin on different cell types by antagonizing its ...
An autoantibody is an antibody (a type of protein) produced by the immune system that is directed against one or more of the individual's own proteins. Many autoimmune diseases (notably lupus erythematosus ) are associated with such antibodies.
The combination of the beta emitter 177 Lu with DOTA-TATE can be used in the treatment of cancers expressing the relevant somatostatin receptors. [16] The U.S. Food and Drug Administration (FDA) considers 177 Lu-dotatate to be a first-in-class medication. [17] Alternatives to 177 Lu-DOTA-TATE include 90 Y (T 1/2 = 64.6 h) DOTA-TATE.
Ads
related to: autoantibody against somatostatin and depression treatment reviewsdoconsumer.com has been visited by 100K+ users in the past month
quizntales.com has been visited by 1M+ users in the past month
consumerhorse.com has been visited by 100K+ users in the past month
benchmarkguide.com has been visited by 10K+ users in the past month